Life Sciences

  • December 09, 2025

    Mistrial Declared In Fla. Opioid Case Against Pharmacies

    A Florida state judge declared a mistrial following a hung jury after two weeks of deliberations in a lawsuit brought by hospitals alleging that Walmart, Walgreens and CVS pharmacies negligently doled out painkillers and contributed to the opioid crisis. 

  • December 09, 2025

    Hagens Berman's Novel DOJ Referral May Have Chilling Effect

    A Pennsylvania federal judge's unusual decision to refer prominent plaintiffs firm Hagens Berman LLP to the U.S. Department of Justice for possible criminal investigation over its pursuit of claims related to morning sickness drug thalidomide could have a chilling effect on lawyers' advocacy, law professors and attorneys said.

  • December 09, 2025

    Medical Appliance Co. Seeks Coverage For SEC Investigation

    A Connecticut-based medical device technology company told a federal court that its insurer wrongfully denied coverage for an investigation by the Securities and Exchange Commission, alleging in a new lawsuit that the federal government's inquiry into the company's insured members triggered its directors and officers policy. 

  • December 09, 2025

    Cooley Adds 30-Person Life Sciences IP Team From Dechert

    A trio of Dechert LLP partners, including the co-chair of its global intellectual property practice, have joined Cooley LLP alongside a team of special counsel, associates and patent agents, the firm announced Tuesday.

  • December 09, 2025

    Teleflex To Divest Multiple Units In Deals Topping $2B

    Simpson Thacher & Bartlett LLP-advised Teleflex Inc. said Tuesday it has agreed to sell several units to private equity firms Montagu and Kohlberg, and to Britain's Intersurgical Ltd., for a combined $2.03 billion in cash.

  • December 08, 2025

    Inari Loses Fed. Circ. Bid To Save Corn Seed Patent Review

    The Federal Circuit Monday rejected Inari Agriculture's mandamus petition claiming the Patent Trial and Appeal Board used an unfairly high standard when denying its request for post-grant review of a Corteva Inc. unit's patent. 

  • December 08, 2025

    1st Circ. Keeps Planned Parenthood Funding Ban In Place

    The First Circuit on Monday issued an administrative stay that temporarily keeps in place a ban on Medicaid funding for Planned Parenthood, pausing a lower court's ruling.

  • December 08, 2025

    What To Do When Jurors Don't 'Trust The Science'

    The pandemic and initiatives from the second administration of President Donald Trump challenging decades of established scientific norms have made science more politicized, and attorneys say picking a jury and presenting scientific evidence is increasingly challenging.

  • December 08, 2025

    4th Circ. Backs EIDP In Dispute Over Annuity Reductions

    The Fourth Circuit backed agricultural chemical giant EIDP Inc. and its retirement plan administrator in a Monday opinion, finding that unambiguous contract language doomed the revival of a lawsuit from a retired employee who said his monthly benefit was unfairly reduced.

  • December 08, 2025

    Chancery Blocks Opt-Out In $32M Emisphere Settlement

    The Delaware Chancery Court on Monday signed off on a $32 million class settlement over Emisphere Technologies Inc.'s $1.8 billion sale to Novo Nordisk AS, rejecting Emisphere investor IsZo Capital LP's push to opt out and pursue its own claims and trimming the investors' fee request to a 23.5% cut of the fund.

  • December 08, 2025

    4 Firms Lead $1.51B TC Transcontinental Packaging Deal

    Private equity-backed ProAmpac on Monday unveiled plans to acquire TC Transcontinental Packaging from TC Transcontinental in a $1.51 billion deal built by four law firms.

  • December 08, 2025

    Hi-Tech Pharma, CEO Want New Trial In Feds' Fraud Case

    A health supplement company's CEO, who was largely acquitted of federal fraud and conspiracy charges last month, asked a Georgia federal judge Friday to toss the lone conviction he faced, arguing that allowing the charge to stand "would constitute a miscarriage of justice."

  • December 08, 2025

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court delivered a busy first week of December, featuring commercial disputes, post-closing merger and acquisition battles and renewed scrutiny of fiduciary conduct ranging from oil and gas investments to healthcare acquisitions. 

  • December 08, 2025

    High Court Wants Feds' Input On Health Workers' Vax Fight

    The U.S. Supreme Court asked Monday for the federal government's input on a group of religious workers' challenge to a pandemic-era New York state policy requiring healthcare providers to make their employees be vaccinated against COVID-19.

  • December 05, 2025

    Juror Who Alleged Misconduct Dismissed From Opioid Trial

    A juror in Florida hospitals' $1.5 billion trial against the three major pharmacy chains over opioid dispensing was dismissed Friday after a judge found that her allegations of serious misconduct against another juror were largely unwarranted.

  • December 05, 2025

    SG Urges Justices To Hear Hikma's 'Skinny Label' Patent Case

    The U.S. solicitor general on Friday urged the U.S. Supreme Court to hear Hikma Pharmaceuticals Inc.'s appeal of a decision reviving a patent suit involving its "skinny label" on a generic heart drug, saying the ruling puts the availability of lower-cost generics at risk.

  • December 05, 2025

    Judge Won't Lift Stay On Hopewell Drug Launch

    A Delaware federal judge has shot down Hopewell Pharma Ventures' bid to lift a regulatory stay on approval of its planned generic version of German drugmaker Merck's blockbuster multiple sclerosis drug Mavenclad.

  • December 05, 2025

    ITC Bans Infringing Drill Bit Imports After Fed. Circ. Remand

    The U.S. International Trade Commission has held that a group of foreign companies is violating Section 337 of the Tariff Act by shipping diamond drill bit components that infringe a U.S. company's patent and issued an order banning such imports after the case was remanded by the Federal Circuit.

  • December 05, 2025

    Cancer Detection Biz Going Public Via $1.1B SPAC Merger

    Cancer detection company Freenome Holdings Inc. announced plans Friday to go public through a merger with special purpose acquisition company Perceptive Capital Solutions Corp. in a deal that gives the combined business a post-transaction equity value of $1.1 billion and was built by three law firms.

  • December 05, 2025

    Pharma Co. Says Ex-Staff Used Secrets To Compete

    Pharmaceutical supplier New Life Medicals (USA) Inc. told a North Carolina state court that a former warehouse manager, a freelance contractor and a business partner conspired to steal confidential information to form a competing venture only 10 miles away.

  • December 05, 2025

    Medline Accused In Chancery Of Withholding $10M Earnout

    A Florida-based holding company and its founder have sued medical supplier Medline in the Delaware Chancery Court, alleging it deliberately refused to make a $10 million payment tied to a 2023 acquisition, missed a hard deadline and is now acting in bad faith to avoid paying the key portion of the sale price.

  • December 05, 2025

    Mass Tort Firms Targeted Over Benicar MDL Fees In NJ Suits

    Robins Kaplan LLP and Pendley Baudin & Coffin were hit with proposed class actions in New Jersey state court from former clients in multidistrict litigation over the blood pressure medication Benicar alleging that the firms overcharged on their fees.

  • December 05, 2025

    CDC Panel Ends Recommendation Of Hepatitis B Shot At Birth

    A panel of federal vaccine advisers on Friday voted to lift a long-standing recommendation that all newborns be given vaccinations for hepatitis B.

  • December 04, 2025

    Wheeling & Appealing: The Latest Must-Know Appellate Action

    Is the False Claims Act constitutional? Will Mark Zuckerberg be deposed in high-profile privacy litigation? Did a major drugmaker's shenanigans cost investors nearly $7 billion? That's a small sample of the intriguing legal questions we're exploring in this preview of December's top appellate action.

  • December 04, 2025

    Class Cert. Denied In Splenda False Ad Suit

    A California federal judge on Wednesday declined to certify a class of consumers who claim that Splenda falsely advertised that its sweetener packets were "suitable for people with diabetes," partly because the lead plaintiff is prediabetic.

Expert Analysis

  • Lessons From 7th Circ.'s Deleted Chat Sanctions Ruling

    Author Photo

    The Seventh Circuit’s recent decision in Pable v. Chicago Transit Authority, affirming the dismissal of an ex-employee’s retaliation claims, highlights the importance of properly handling the preservation of ephemeral messages and clarifies key sanctions issues, says Philip Favro at Favro Law.

  • Breaking Down The Proposed Hemp Bill

    Author Photo

    A proposed bill in the U.S. House of Representatives, recently approved by the House Appropriations Committee, contains a rider that would significantly change the definition of hemp and dramatically reshape the current hemp-derived product market, say attorneys at King & Spalding.

  • Assessing Federal Securities Class Action Stats In '25 So Far

    Author Photo

    The settlement amount as a percentage of damages in securities class actions has continued to decline in the first half of 2025, a trend that may be important for assessing exposure and risk in future securities litigation, say analysts at Analysis Group.

  • Series

    Quilting Makes Me A Better Lawyer

    Author Photo

    Turning intricate patterns of fabric and thread into quilts has taught me that craftsmanship, creative problem-solving and dedication to incremental progress are essential to creating something lasting that will help another person — just like in law, says Veronica McMillan at Kramon & Graham.

  • How Agentic AI Is Testing The Limits Of Patent Law

    Author Photo

    While a recent Swiss court ruling suggests that human-centric rules regarding inventorship will likely remain in place for the near future, it captures a core tension confronting patent systems worldwide as the technology producing patent-worthy ideas is becoming increasingly autonomous, says Matthew Carey at Marshall Gerstein.

  • How To Prep For Potential Passage Of SAFER Banking Act

    Author Photo

    The Secure and Fair Enforcement Regulation, or SAFER, Banking Act, could fundamentally reshape how financial institutions interact with cannabis businesses, so operators that move now to get their house in order will be best positioned to capitalize if and when change comes, says Alex Leonowicz at Howard & Howard.

  • A Former PTAB Judge Weighs The End Of Remote Hearings

    Author Photo

    Former Patent Trial and Appeal Board Judge Amanda Wieker, now at McGuireWoods, examines the costs and benefits of the PTAB's impending in-person hearing requirement, and offers suggestions for making the most out of this new regime.

  • The Future Of Lab-Test Regs After FDA Rescinds Rule

    Author Photo

    The U.S. Food and Drug Administration recently rescinded its laboratory-developed tests rule in response to a Texas federal court decision this spring, reinforcing a separation of authority between the FDA and the Centers for Medicare & Medicaid Services, and calling into question the FDA's role in overseeing such tests without congressional action, say attorneys at Venable.

  • SDNY Ruling Reinforces Joint Steering Committee Obligations

    Author Photo

    The recent Southern District of New York decision in ChemImage v. Johnson & Johnson makes joint steering committees a valuable tool in strategic relationships, as provisions for such committees can now be wielded to demand attention to core issues, say Lisa Bernstein at the University of Chicago Law School, and Reginald Goeke and Brad Peterson at Mayer Brown.

  • What 2 Profs Noticed As Transactional Law Students Used AI

    Author Photo

    After a semester using generative artificial intelligence tools with students in an entrepreneurship law clinic, we came away with numerous observations about the opportunities and challenges such tools present to new transactional lawyers, say professors at Cornell Law School.

  • What Patent Claim 'Invalidity' Means In Different Forums

    Author Photo

    A recent Federal Circuit order allowing a patent suit to proceed despite similar claims being invalidated in an inter partes review underscores how fractured the patent litigation landscape has become, leading to critical nuances in how district courts, the U.S. International Trade Commission and Patent Trial and Appeal Board treat invalidity, says Jason Hoffman at BakerHostetler.

  • Rebuttal

    BigLaw Settlements Should Not Spur Ethics Deregulation

    Author Photo

    A recent Law360 op-ed argued that loosening law firm funding restrictions would make BigLaw firms less inclined to settle with the Trump administration, but deregulating legal financing ethics may well prove to be not merely ineffective, but counterproductive, says Laurel Kilgour at the American Economic Liberties Project.

  • How Big Pharma Has Responded To FTC Delisting Demands

    Author Photo

    Looking at some statistics concerning how pharmaceutical companies have responded to the Federal Trade Commission's recent challenges to Orange Book listings raises several possible hypotheses about the FTC's strategy and effectiveness, say Ratib Ali and Celia Lu at Competition Dynamics.

  • 5 Ways Lawyers Can Earn Back The Public's Trust

    Author Photo

    Amid salacious headlines about lawyers behaving badly and recent polls showing the public’s increasingly unfavorable view of attorneys, we must make meaningful changes to our culture to rebuild trust in the legal system, says Carl Taylor at Carl Taylor Law.

  • USPTO's AI Tool Redefines Design Patent Landscape

    Author Photo

    The U.S. Patent and Trademark Office's newly introduced DesignVision tool for artificial intelligence-powered image searching represents a dramatic shift in how design patent applications are examined, necessitating new strategies for patent practitioners, says Matthew Epstein at Dinsmore.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.